Attached files
Exhibit 99.2
Cellular Biomedicine Group (CBMG) Appoints Dr. Xia Meng as Chief
Operating Officer to Lead Commercialization of the Company’s
CAR-T and Stem Cell Products
SHANGHAI, China and CUPERTINO, Calif., June 26,
2017 /GlobeNewswire/ — Cellular Biomedicine Group
Inc. (NASDAQ: CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm
engaged in the development of effective immunotherapies for cancer
and stem cell therapies for degenerative diseases, today announced
the appointment of Dr. Xia Meng as Chief Operating Officer for the
Company.
“We are very pleased to welcome Dr. Meng to the CBMG
team,” said Tony (Bizuo) Liu, Chief Executive Officer for the
Company. “Dr. Meng brings with her a wealth of experience in
the biopharmaceutical fields in China and internationally, and a
track record of successful drug development and commercialization.
As a seasoned executive who has completed multiple approved IND
applications in China, she will be instrumental in executing our
near-term strategic plans including IND applications for our lead
product candidates CARD-1 and CALL-1 Chimeric Antigen Receptor
T-Cell (CAR-T) cancer therapies and AlloJoinTM
‘Off-the-Shelf’ Allogeneic
Human Adipose-derived Mesenchymal Stem Cell for the treatment of
Knee Osteoarthritis (KOA). This is of critical importance as CBMG
enters a pivotal growth phase.”
“CBMG is a highly innovative company, well positioned to
bring to market several therapies to effectively address unmet
medical needs,” commented Dr. Meng. “I look forward to
an interchange of knowledge with their seasoned executive and
scientific teams and to help maximize the significant commercial
potential and social impact that the Company’s robust
pipeline may accomplish.”
About Dr. Xia Meng
Dr. Xia Meng has over 18 years of broad experience in
biopharmaceutical and biotechnological industries, from research
& development and product development to marketing, sales,
business and management, both in domestic and international
companies. She worked previously as General Manager of Transgene Tasly
(Tianjin) Biopharmaceutical Co., Ltd., and Transgene
Biopharmaceutical Technology (Shanghai) Co., Ltd., Asia Pacific
Scientific Director, Global Oncology Program Director, Asia Pacific
Regional Business Manager of bioMérieux and Head of Fudan
University Shanghai Cancer Center - Institute Mérieux
Laboratory.
Dr.
Meng has driven two rounds of viral vector therapeutics product
development in China, and experienced all the factors of biologics
development processes, such as concept, construction, pharmacology
study, toxicity study, CMC, and quality control. She has conducted
two successful IND applications in China, with one approved in
2004, and the other approved in 2017.
Dr.
Meng received her B.S. degree from Wuhan University, China,
obtained her PhD at the University of Paris VI (Université
Pierre et Marie Curie, Paris) and completed more than 10 years of
basic research in notable laboratories INSERM and Curie Institute
in France.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc.
(NASDAQ: CBMG) develops proprietary cell therapies for the
treatment of cancer and degenerative diseases. We conduct
immuno-oncology and stem cell clinical trials in China using
products from our integrated GMP laboratory. Our GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. CBMG recently commenced two Phase I human clinical
trials in China using CAR-T to treat Refractory Diffuse Large
B-cell Lymphoma (DLBCL), a Phase I human clinical trial to treat
relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia
(ALL), as well as an ongoing Phase I trial in China for
AlloJoinTM
(CBMG’s
“Off-the-Shelf” Allogeneic Human Adipose-derived
Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis
(KOA). CBMG was recently awarded $2.29 million from the California
Institute for Regenerative Medicine (CIRM) to support pre-clinical
studies of AlloJoinTM
for Knee Osteoarthritis in the United
States. The Company also recently announced a strategic partnership
with GE Healthcare Life Sciences China to establish a joint
technology laboratory to develop control processes for the
manufacture of CAR-T and stem cell therapies. To learn more about
CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports
filed with the Securities and Exchange Commission, quarterly
reports on form 10-Q, current reports on form 8-K and annual
reports on form 10-K. Forward-looking statements may be identified
by terms such as "may," "will," "expects," "plans," "intends,"
"estimates," "potential," or "continue," or similar terms or the
negative of these terms. Although CBMG believes the expectations
reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity,
performance or achievements will be obtained. CBMG does not have
any obligation to update these forward-looking statements other
than as required by law.
Contact:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com